EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Route‐Gated Lymphatic Delivery of Antigen‐Only Gliadin Nanoparticles for Celiac Disease‐Oriented Immune Modulation

Jiaqi Zhang, Yuan Gao, Yinan Song, Chuyi Bao, Zhaoying Ren, Shiyu Yuan, Yang Yang, Yongjun Wang, Hongzhuo Liu

Advanced Healthcare Materials · 2026-11-10

DOI: 10.1002/adhm.71970 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Celiac disease (CeD) lacks approved pharmacologic therapy. Targeted delivery of antigens to immune inductive sites may provide a means to modulate pathogenic immune responses, yet practical delivery remains challenging. We show that minimal, adjuvant‐free, self‐assembled gliadin nanoparticles (L@GNP) attenuated antibody boosting after exploratory intravenous (i.v.) pre‐exposure. Both soluble gliadin and L@GNP attenuated subsequent anti‐gliadin antibody boosting under the tested i.v. conditions, with L@GNP providing a particulate antigen format with a controlled surface antigen positive rate. Rather than i.v. dosing, subcutaneous (s.c.) administration of L@GNP preferentially accessed draining lymphoid tissues and exhibited temporally coordinated uptake by multiple antigen‐presenting cell (APC) populations, characterized by early CD11b+ myeloid‐cell capture, transient B220+ cell involvement, and sustained enrichment in CD11c+ APCs at later time points. In a short‐term CeD‐like mouse model, L@GNP preserved villus architecture as indicated by higher V/C and reduced intestinal inflammation by lowering Transglutaminase 2 (TGM2) and key cytokines, rebalanced Th1/Th2, and increased Foxp3 expression, whereas a rapamycin‐loaded counterpart (R/L@GNP) did not confer additional benefit at matched antigen doses. These data highlight route‐gated lymphatic access and antigen‐only simplicity as materials design principles for immunomodulatory nanomedicines.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →